149 related articles for article (PubMed ID: 38601325)
1. Cataplexy response with extended-release once-nightly sodium oxybate: Post hoc responder analyses from the phase 3 REST-ON clinical trial.
Thorpy MJ; Kushida CA; Bogan R; Ajayi AO; Corser BC; Gudeman J
Sleep Med X; 2024 Dec; 7():100109. PubMed ID: 38601325
[TBL] [Abstract][Full Text] [Related]
2. Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial.
Roth T; Dauvilliers Y; Thorpy MJ; Kushida C; Corser BC; Bogan R; Rosenberg R; Dubow J; Seiden D
CNS Drugs; 2022 Apr; 36(4):377-387. PubMed ID: 35380374
[TBL] [Abstract][Full Text] [Related]
3. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy.
Kushida CA; Shapiro CM; Roth T; Thorpy MJ; Corser BC; Ajayi AO; Rosenberg R; Roy A; Seiden D; Dubow J; Dauvilliers Y
Sleep; 2022 Jun; 45(6):. PubMed ID: 34358324
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial.
Dauvilliers Y; Roth T; Bogan R; Thorpy MJ; Morse AM; Roy A; Dubow J; Gudeman J
Sleep; 2023 Nov; 46(11):. PubMed ID: 37246913
[TBL] [Abstract][Full Text] [Related]
5. Improvement in sleep latency with extended-release once-nightly sodium oxybate for the treatment of adults with narcolepsy: Analysis from the phase 3 REST-ON clinical trial.
Thorpy MJ; Kushida CA; Bogan R; Winkelman J; Ohayon MM; Shapiro CM; Gudeman J
Sleep Med X; 2024 Dec; 7():100113. PubMed ID: 38774037
[TBL] [Abstract][Full Text] [Related]
6. Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary.
Roth T; Thorpy MJ; Kushida CA; Horsnell M; Gudeman J
J Comp Eff Res; 2023 Dec; 12(12):e230133. PubMed ID: 37971303
[TBL] [Abstract][Full Text] [Related]
7. Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.
Dauvilliers Y; Šonka K; Bogan RK; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Chen A; Black J; Skobieranda F; Thorpy MJ
CNS Drugs; 2022 Jun; 36(6):633-647. PubMed ID: 35635687
[TBL] [Abstract][Full Text] [Related]
8. Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary.
Rosenberg R; Braceras R; Macfadden W; Candler S; Black J; Ruoff C
Neurol Ther; 2023 Dec; 12(6):1805-1820. PubMed ID: 37755650
[TBL] [Abstract][Full Text] [Related]
9. Effect of sodium oxybate on body mass index in pediatric patients with narcolepsy.
Dauvilliers Y; Lammers GJ; Lecendreux M; Maski K; Kansagra S; Black J; Parvataneni R; Chen A; Wang YG; Plazzi G
J Clin Sleep Med; 2024 Mar; 20(3):445-454. PubMed ID: 37942930
[TBL] [Abstract][Full Text] [Related]
10. Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: Phase 1 study in healthy volunteers.
Bogan R; Thorpy MJ; Winkelman JW; Dubow J; Gudeman J; Seiden D
Sleep Med; 2022 Dec; 100():442-447. PubMed ID: 36252412
[TBL] [Abstract][Full Text] [Related]
11. Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis.
Alshaikh MK; Tricco AC; Tashkandi M; Mamdani M; Straus SE; BaHammam AS
J Clin Sleep Med; 2012 Aug; 8(4):451-8. PubMed ID: 22893778
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy.
Bogan RK; Foldvary-Schaefer N; Skowronski R; Chen A; Thorpy MJ
CNS Drugs; 2023 Apr; 37(4):323-335. PubMed ID: 36947322
[TBL] [Abstract][Full Text] [Related]
13. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.
Black J; Swick T; Bogan R; Lai C; Carter LP
Sleep Med; 2016 Aug; 24():57-62. PubMed ID: 27810187
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.
Lecendreux M; Plazzi G; Dauvilliers Y; Rosen CL; Ruoff C; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
J Clin Sleep Med; 2022 Sep; 18(9):2217-2227. PubMed ID: 35689598
[TBL] [Abstract][Full Text] [Related]
15. Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Bogan RK; Roth T; Schwartz J; Miloslavsky M
J Clin Sleep Med; 2015 Apr; 11(4):427-32. PubMed ID: 25580605
[TBL] [Abstract][Full Text] [Related]
16. Preferences for Attributes of Sodium Oxybate Treatment: A Discrete Choice Experiment in Patients with Narcolepsy.
Dubow J; Avidan AY; Corser B; Athavale A; Seiden D; Kushida C
Patient Prefer Adherence; 2022; 16():937-947. PubMed ID: 35422617
[TBL] [Abstract][Full Text] [Related]
17. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy.
Black J; Pardi D; Hornfeldt CS; Inhaber N
J Clin Sleep Med; 2010 Dec; 6(6):596-602. PubMed ID: 21206549
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.
Bogan RK; Thorpy MJ; Dauvilliers Y; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Tang L; Skobieranda F; Šonka K
Sleep; 2021 Mar; 44(3):. PubMed ID: 33184650
[TBL] [Abstract][Full Text] [Related]
19. Dosing and transition characteristics in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study.
Husain AM; Zee PC; Leary EB; Fuller DS; Macfadden W; Candler S; Whalen M; Bae CJ
Sleep Med; 2024 Jan; 113():328-337. PubMed ID: 38103464
[TBL] [Abstract][Full Text] [Related]
20. Population and Noncompartmental Pharmacokinetics of Sodium Oxybate Support Weight-Based Dosing in Children and Adolescents With Narcolepsy With Cataplexy.
Chen C; Rosen CL; Ruoff C; Boyce LH; Parvataneni R; Zomorodi K; Brantley S; Sale M; Plazzi G
Clin Transl Sci; 2020 Sep; 13(5):932-940. PubMed ID: 32216084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
